Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 20;38(21):2454-2462.
doi: 10.1200/JCO.20.00199. Epub 2020 Apr 7.

Breast Cancer: 45 Years of Research and Progress

Gabriel N Hortobagyi  1
Affiliations

Breast Cancer: 45 Years of Research and Progress

Gabriel N Hortobagyi. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Breast Cancer: 45 Years of Research and Progress

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Gabriel N. Hortobagyi

Consulting or Advisory Role: Novartis, Peregrine Pharmaceuticals, Agendia

Research Funding: Novartis (Inst)

Travel, Accommodations, Expenses: Novartis

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
History of breast cancer treatment: Timeline. Integration of various discoveries that led to changes in the standard of care. Discoveries are displayed by approximate year of incorporation into practice. AI, aromatase inhibitor; APBI, accelerated partial breast irradiation; IMRT, intensity-modulated radiotherapy; LHRH, luteinizing hormone-releasing hormone; RT, radiotherapy; SERM, selective estrogen receptor modulator; T-DM1, trastuzumab emtansine.
FIG 2.
FIG 2.
Systemic management of primary breast cancer. The four generally accepted clinical-molecular subtypes are shown, along with standard-of-care therapeutic approaches to each subtype. AI, aromatase inhibitor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; RS, recurrence score; SERM, selective estrogen receptor modulator.
FIG 3.
FIG 3.
Five-year relative survival rates for breast cancer: 1973-2019. Numbers represent 5-year relative survival figures. The change between 1973 and 2019 reflects the progress in detection and treatment. Data are given as percent 5-year survival.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7-34, 2019 - PubMed
    1. National Cancer Institute : National Cancer Act of 1971. https://dtp.cancer.gov/timeline/flash/milestones/M4_Nixon.htm
    1. Fisher B, Wolmark N: New concepts in the management of primary breast cancer. Cancer 36:627-632, 1975. (suppl) - PubMed
    1. Welbourn RB, Burn JI: Treatment of advanced mammary cancer. N Engl J Med 287:398-400, 1972 - PubMed
    1. Carter SK: The chemical therapy of breast cancer. Semin Oncol 1:131-144, 1974 - PubMed

Publication types